Spectrum Pharmaceuticals Up 12% (SPPI)

Spectrum Pharmaceuticals SPPI is up more than 12% in early trade after the company's Fusilev drug was approved by the FDA for colorectal cancer. Fusilev had already won approval for osteosarcoma, a common form of bone cancer. Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology.